May 5, 2020
Janssen Inc. et al v Teva Canada Limited
Featuring: Peter Wilcox and Marian Wolanski
We successfully represented Janssen in this patent infringement action under the new PMNOC Regulations concerning Janssen’s Invega Sustenna (paliperidone palmitate) product used to treat schizophrenia. Following a two week trial, Justice Manson agreed that Teva’s paliperidone palmitate product would directly infringe certain of the patent claims. Teva’s argument that the claimed subject-matter was obvious was rejected.